Heatwurx (PCSA) Competitors $0.23 +0.00 (+1.58%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.23 0.00 (-0.48%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. RNAZ, ACXP, DWTX, XFOR, APRE, SNGX, SONN, CHRO, ADXN, and CLRBShould you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include TransCode Therapeutics (RNAZ), Acurx Pharmaceuticals (ACXP), Dogwood Therapeutics (DWTX), X4 Pharmaceuticals (XFOR), Aprea Therapeutics (APRE), Soligenix (SNGX), Sonnet BioTherapeutics (SONN), Chromocell Therapeutics (CHRO), Addex Therapeutics (ADXN), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Heatwurx vs. Its Competitors TransCode Therapeutics Acurx Pharmaceuticals Dogwood Therapeutics X4 Pharmaceuticals Aprea Therapeutics Soligenix Sonnet BioTherapeutics Chromocell Therapeutics Addex Therapeutics Cellectar Biosciences TransCode Therapeutics (NASDAQ:RNAZ) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability. Do institutionals and insiders believe in RNAZ or PCSA? 91.9% of Heatwurx shares are held by institutional investors. 0.0% of TransCode Therapeutics shares are held by company insiders. Comparatively, 9.6% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, RNAZ or PCSA? TransCode Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Heatwurx has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Does the media refer more to RNAZ or PCSA? In the previous week, Heatwurx had 3 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for Heatwurx and 0 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.00 beat Heatwurx's score of -1.33 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TransCode Therapeutics Neutral Heatwurx Negative Which has preferable earnings and valuation, RNAZ or PCSA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$16.75MN/AN/AHeatwurxN/AN/A-$11.85M-$3.08-0.08 Is RNAZ or PCSA more profitable? Heatwurx's return on equity of -319.56% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -578.88% -222.61% Heatwurx N/A -319.56%-232.40% Do analysts recommend RNAZ or PCSA? TransCode Therapeutics currently has a consensus price target of $280.00, suggesting a potential upside of 2,529.11%. Heatwurx has a consensus price target of $2.00, suggesting a potential upside of 765.43%. Given TransCode Therapeutics' higher possible upside, analysts plainly believe TransCode Therapeutics is more favorable than Heatwurx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Heatwurx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHeatwurx beats TransCode Therapeutics on 5 of the 9 factors compared between the two stocks. Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricHeatwurxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.70M$2.51B$5.48B$9.56BDividend YieldN/A1.78%3.99%4.17%P/E Ratio-0.0819.6629.9325.14Price / SalesN/A425.10375.2276.13Price / CashN/A165.0335.9458.58Price / Book0.504.198.105.59Net Income-$11.85M$31.61M$3.26B$265.48M7 Day Performance9.27%0.95%0.68%1.22%1 Month Performance8.80%2.90%2.45%0.39%1 Year Performance-86.16%4.11%27.72%23.47% Heatwurx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAHeatwurx2.1632 of 5 stars$0.23+1.6%$2.00+765.4%-87.1%$2.70MN/A-0.0820News CoveragePositive NewsEarnings ReportUpcoming EarningsGap DownHigh Trading VolumeRNAZTransCode Therapeutics1.9611 of 5 stars$11.40-0.9%$280.00+2,356.1%-99.9%$9.59MN/A0.009Upcoming EarningsACXPAcurx Pharmaceuticals2.1845 of 5 stars$0.29-4.8%$8.00+2,636.0%-88.1%$9.44MN/A-0.423Upcoming EarningsDWTXDogwood Therapeutics1.4452 of 5 stars$4.86+0.2%$10.00+105.8%N/A$9.27MN/A-0.275News CoverageXFORX4 Pharmaceuticals4.4607 of 5 stars$1.58-1.3%$72.33+4,478.1%-92.3%$9.26M$2.56M0.7480APREAprea Therapeutics2.8644 of 5 stars$1.70+2.4%$15.50+811.8%-49.2%$9.18M$1.50M-0.727Upcoming EarningsSNGXSoligenix2.0988 of 5 stars$3.11+13.5%$6.00+92.9%-3.2%$8.94M$120K-0.7220High Trading VolumeSONNSonnet BioTherapeutics2.4967 of 5 stars$2.81flat$20.00+611.7%-51.4%$8.90M$20K0.0010Upcoming EarningsGap UpCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-81.2%$8.69MN/A-1.084Gap UpHigh Trading VolumeADXNAddex Therapeutics2.9153 of 5 stars$8.24+1.7%$30.00+264.3%+5.5%$8.58M$460K-24.2230CLRBCellectar Biosciences2.8059 of 5 stars$5.06+7.2%$375.00+7,311.1%-91.7%$8.54MN/A-0.2310News CoverageUpcoming Earnings Related Companies and Tools Related Companies TransCode Therapeutics Alternatives Acurx Pharmaceuticals Alternatives Dogwood Therapeutics Alternatives X4 Pharmaceuticals Alternatives Aprea Therapeutics Alternatives Soligenix Alternatives Sonnet BioTherapeutics Alternatives Chromocell Therapeutics Alternatives Addex Therapeutics Alternatives Cellectar Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCSA Stock Alerts